On September 9, 2019 Novocure (NASDAQ: NVCR) reported 27 presentations on Tumor Treating Fields, including four oral presentations, will be featured at the American Society for Radiation Oncology (ASTRO) 2019 Annual Meeting, Sept. 15 through Sept. 18 in Chicago (Press release, NovoCure, SEP 9, 2019, View Source [SID1234539381]). The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference. External authors prepared 16 of the presentations, pointing to a growing interest in Novocure’s proprietary Tumor Treating Fields platform within the radiation oncology community.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation highlights include a subgroup analysis of the STELLAR trial by radiological response patterns in malignant pleural mesothelioma and the first presentation of in vitro data combining treatment with Tumor Treating Fields and chemotherapy in gastric cancer.

"The presence of Tumor Treating Fields at the ASTRO Annual Meeting has grown substantially over the last three years," said Novocure’s Chief Medical Officer Ely Benaim. "We are excited to continue our partnership with the radiation oncology community to help establish Tumor Treating Fields as an important treatment for solid tumors. We look forward to participating in the exchange of scientific information at one of the premier meetings for radiation oncologists."

Oral Presentations

(Presentation 1070) Radiological Response Patterns in Malignant Pleural Mesothelioma (MPM): Subgroup Analyses of the Phase 2 STELLAR Trial of TTFields plus Chemotherapy for First-Line Treatment. F. Grosso. 8:40 to 8:45 a.m. CDT Monday, Sept.16.

(Presentation 1102) Blood Brain Barrier (BBB) Integrity is Affected By Tumor Treating Fields (TTFields) in Vitro and In Vivo. C. Hagemann. 4:25 to 4:30 p.m. CDT Monday, Sept.16.

(Presentation 212) Creating Conductivity Maps at 200 Khz of Brain and Tumor Tissue of Glioblastoma Patients with Water-Content Based Electric Properties Tomography. N. Gentilal. 1:55 to 2:05 p.m. CDT Wednesday, Sept. 18.

(Presentation 1277) Tumor Treating Fields Delivery to the Abdomen Is Unlikely to Cause Thermal Tissue Damage: Results of an Extensive Computational Analysis. N. Gentilal. 2:25 to 2:30 p.m. CDT Wednesday, Sept. 18.

Joint Interactive Session

Novel targeted therapies/Immuno-oncology and Clinical Trials/TTF. M. Ahluwalia. 4:32 to 4:44 p.m. CDT Monday, Sept. 16.

Poster Presentations

(3109) Efficacy and Thermal Safety of Tumor Treating Fields Delivered to the Thorax: A Simulation-Based Study. Z. Bomzon. 1:15 to 2:30 p.m. CDT Sunday, Sept. 15.

(3116) Malignant Pleural Mesothelioma: Survival Meta-Analysis from 15 Years of a Standard Systemic Therapy. J. Friedberg. 1:15 to 2:30 p.m. CDT Sunday, Sept. 15.

(3254) Clinical Value of TTFields Treatment in Mesothelioma Using ASCO (Free ASCO Whitepaper) and ESMO (Free ESMO Whitepaper) Frameworks. J. Kelly. 1:15 to 2:30 p.m. CDT Sunday, Sept. 15.

(3611) Animal Studies Evaluating the Safety of Tumor Treating Fields (TTFields) Alone and in Combination with Chemotherapy Agents Demonstrate No Additional Toxicities. M. Giladi. 1:15 to 2:30 p.m. CDT Sunday, Sept. 15.

(2159) Delivering Uniform TTFields Distribution to the Brain. Z. Bomzon. 10:45 to 12 p.m. CDT Monday, Sept. 16.

(2214) Prostaglandin E Receptor 3 Mediates Resistance to Tumor Treating Fields in Glioblastoma Cells. D. Chen. 10:45 to 12 p.m. CDT Monday, Sept. 16.

(2222) Tumor Treating Fields Combined with Radiotherapy and Temzolomide for the Treatment of Newly Diagnosed Glioblastoma: Final Results from a Pilot Study. R. Grossman. 10:45 to 12 p.m. CDT Monday, Sept. 16.

(2226) Analysis of the EF-14 Phase 3 Trial Reveals That Tumor Treating Fields Alter Progression Patterns in Glioblastoma. S. Jeyapalan. 10:45 to 12 p.m. CDT Monday, Sept. 16.

(2287) A Proof of Concept Study for Simulating Heat Transfer in Patients Treated with Tumor Treating Fields. Z. Bomzon. 10:45 to 12 p.m. CDT Monday, Sept. 16.

(2240) Single Institutional Experience with Tumor Treating Field Compliance and Overall Survival in Patients with Primary Glioblastoma. K. Qualls. 10:45 a.m. to 12 p.m. CDT Monday, Sept. 16

(3003) Treating Elderly Glioblastoma Patients > 65 Years with TTFields: A Cost-Effectiveness Perspective. F. Leonard. 1 to 2:15 p.m. CDT Tuesday, Sept. 17.

(3362) Updated Meta-Analysis of Toxicity Data in Thoracic and Abdominal Malignancies from Clinical Trials in Tumor Treating Fields. I. Vergote. 1 to 2:15 p.m. CDT Tuesday, Sept. 17.

(3486) Exploiting Conditional Vulnerabilities Caused By the Systems Level Effects of Tumor Treating Fields. M. Story. 1 to 2:15 p.m. CDT Tuesday, Sept. 17.

(3498) TTFields Induces Immunogenic Cell Death and Sting Pathway Activation through Cytoplasmic Double-Stranded DNA in Glioblastoma Cells. D. Chen. 1 to 2:15 p.m. CDT Tuesday, Sept. 17.

(3541) Tumor Treating Fields (TTFields) Suppress Tunneling Nanotube Formation in Malignant Mesothelioma. A. Sarkari. 1 to 2:15 p.m. CDT Tuesday, Sept. 17.

(3581) Patient-Derived Metastatic Non-Small Cell Lung Cancer (NSCLC) Cell Lines from Untreated and Treated Patients Are Sensitive to Tumor Treating Fields (TTFields) in Vitro. S. Michelhaugh. 1 to 2:15 p.m. CDT Tuesday, Sept. 17.

(3573) Tumor Treating Fields (TTFields) Plus Sorafenib Is Safe and Effective in Hepatocellular Carcinoma Tested in Vitro and in an Animal Model. S. Davidi. 1 to 2:15 p.m. CDT Tuesday, Sept.17.

(3514) Immunogenic Cell Death Induced by Tumor Treating Fields (TTFields) Enhances Efficacy When Combined with Anti-PD-1 Therapy in Lung and Colon Cancer Animal Models. T. Voloshin. 1 to 2:15 p.m. CDT Tuesday, Sept. 17.

(3582) Efficacy of Tumor Treating Fields (TTFields) in Combination with Cisplatin or Pemetrexed for the Treatment of Mesothelioma in Vitro and in Vivo. M. Munster. 1 to 2:15 p.m. CDT Tuesday, Sept. 17.

(3587) The Combined Treatment of 150 kHz Tumor Treating Fields (TTFields) and FOLFOX Inhibit Gastric Cancer in Vitro. E. Zeevi. 1 to 2:15 p.m. CDT Tuesday, Sept. 17.

(3845) Tumor Treating Fields Therapy Influences Patterns of Failure in Glioblastoma Patients in a Dose-Dependent Manner: A Multidisciplinary Analysis of the Randomized Phase III EF-14 Clinical Trial. M. Ballo. 1 to 2:15 p.m. CDT Tuesday, Sept. 17.

(3857) Optimizing Transducer Array Layout for the Treatment of Pancreatic Cancer Using Tumor Treating Fields (TTFields) in the Phase 3 PANOVA-3 Trial. Z. Bomzon. 1 to 2:15 p.m. CDT Tuesday, Sept. 17.